What is Akeso?
Akeso, Inc. is a pioneering biopharmaceutical company dedicated to the research and development of innovative antibody drugs targeting major diseases such as cancer, autoimmune disorders, and metabolic diseases. The company leverages its proprietary ACE Platform, which integrates advanced technologies like Tetrabody and Dual-Shield ADCT, to create a comprehensive end-to-end drug research and development pipeline. Akeso's mission is to address unmet clinical needs globally by providing affordable, innovative antibody drug solutions, thereby generating substantial commercial and social value. The company actively pursues strategic partnerships for collaborative product development and licensing opportunities, both within China and internationally.
How much funding has Akeso raised?
Akeso has raised a total of $422.2M across 4 funding rounds:
Series A
$19.5M
Series B
$2.7M
Series D
$150M
Share Placement
$250M
Series A (2015): $19.5M with participation from Qianhai Xino, Shenzhen Capital Group, and CCB Capital
Series B (2017): $2.7M led by ShenZhen GTJA Investment Group
Series D (2019): $150M supported by AIHC Capital, Sino Biopharmaceutical,, Lake Bleu Capital, OrbiMed, and Loyal Valley Capital
Share Placement (2024): $250M, investors not publicly disclosed
Key Investors in Akeso
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and diagnostics. The firm invests in companies at various stages of development, from early-stage ventures to established organizations scaling proven solutions, leveraging deep industry expertise to support strategic initiatives and market positioning.
Loyal Valley Capital
Loyal Valley Capital is an investment firm that likely focuses on strategic capital deployment within its target sectors, potentially including biotechnology and healthcare, given its participation in Akeso's funding rounds. The firm's involvement suggests a strategic interest in innovative companies driving advancements in medical science and therapeutic solutions.
AIHC Capital
AIHC Capital is an investment entity that has participated in significant funding rounds for Akeso, indicating a strategic interest in the biopharmaceutical sector and innovative drug development. The firm's backing suggests a focus on companies with strong research platforms and potential for high impact in addressing critical health challenges.
What's next for Akeso?
With its latest major strategic investment, Akeso is poised for accelerated growth and expansion. The significant capital infusion is expected to fuel further advancements in its drug development pipeline, potentially enabling the company to scale its operations, broaden its research initiatives, and pursue new market opportunities. This strategic financing suggests a strong investor confidence in Akeso's innovative platform and its potential to deliver impactful therapeutic solutions, positioning the company for a significant phase of development and market penetration.
See full Akeso company page
